BAY2701439 / Bayer - LARVOL DELTA

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov) - P1 | N=14 | Completed | Sponsor: Bayer | Active, not recruiting ➔ Completed

Metastases • Trial completion • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • HER-2

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Bayer | Trial completion date: Apr 2024 ➔ Sep 2023 | Trial primary completion date: Mar 2024 ➔ Aug 2023

Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • HER-2

[VIRTUAL] HER2-TTC: A Targeted thorium conjugate to treat HER2 expressing cancers with potent alpha radiation (AACR 2021) - P1 | "HER2-TTC (BAY 2701439) is a new representative of the Targeted Thorium Conjugates (TTCs), a novel class of radiotherapeutics for the treatment of cancer...HER2-TTC has also demonstrated synergistic efficacy in combination with olaparib in a BRCAmut model...HER2-TTC has recently entered a First in Human study (NCT04147819) in patients with advanced tumors that express HER2. These include HER2 high expressing (IHC3+ or ISH+) breast and gastric/gastroesophageal carcinoma relapsed/refractory to trastuzumab/T-DM1, cancers with low HER2 expression, and other tumors that express HER2 such as colorectal cancer, non-small cell lung cancer, salivary, bladder and endometrial tumors."

Bladder Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastroesophageal Cancer • Gastrointestinal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • HER-2

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov) - P1 | N=14 | Active, not recruiting | Sponsor: Bayer | Recruiting ➔ Active, not recruiting | N=213 ➔ 14 | Trial completion date: Jul 2028 ➔ Apr 2024 | Trial primary completion date: Jul 2026 ➔ Mar 2024

Enrollment change • Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov) - P1 | N=213 | Recruiting | Sponsor: Bayer | Trial completion date: Jul 2027 ➔ Jul 2028 | Trial primary completion date: Jul 2025 ➔ Jul 2026

Trial completion date • Trial primary completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov) - P1; N=213; Recruiting; Sponsor: Bayer; Trial completion date: Sep 2026 ➔ Jul 2027; Trial primary completion date: Dec 2024 ➔ Jul 2025

Clinical • Trial completion date • Trial primary completion date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • HER-2

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov) - P1; N=176; Recruiting; Sponsor: Bayer; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • HER-2

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov) - P1; N=176; Not yet recruiting; Sponsor: Bayer; Initiation date: Mar 2020 ➔ Sep 2020

Clinical • Trial initiation date • Breast Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • HER-2

A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein (clinicaltrials.gov) - P1; N=176; Not yet recruiting; Sponsor: Bayer; Trial completion date: May 2027 ➔ Sep 2026; Trial primary completion date: Apr 2025 ➔ Oct 2024

Clinical • Trial completion date • Trial primary completion date • HER2